Fig. 5: TSA treatments sensitizes the TNBC cells to chemotherapeutic agents.

a MDA-MB-231 cells were treated with 1 μM TSA for hours as indicated and immunoblotted with the CHFR and β-actin antibodies. b MDA-MB-231 cells were treated with different concentrations of TSA for 36 h and immunoblotted with the ZEB1 and β-actin antibodies. c MDA-MB-231 cells were treated with TSA as indicated for 36 h. After fixing with 10% methanol, the cells were then stained with 1:1000 crystal violet. d–f MDA-MB-231 cells were co-treated with 0.6 μM TSA and 5-FU (d), DOX (e), or paclitaxel (f) for 36 h. After fixing with 10% methanol, the cells were then stained with 1:1000 crystal violet. g–i LM2 cells were treated and analyzed as described in d–f. Significance of Mock versus TSA is shown. n = 3 wells per group. Data in c and d–i are the mean of biological replicates from a representative experiment, and error bars indicate s.e.m. Statistical significance was determined by a two-tailed, unpaired Student’s t test. The experiments were repeated three times.